Ranibizumab Market Report 2026

Ranibizumab Market Overview

• Ranibizumab market size has reached to $2.76 billion in 2025 • Expected to grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 3.6% • Growth Driver: Global Rise In Eye Diseases Drives Growth Of Ranibizumab Market • Market Trend: Embracing Cost-Effective Therapies With Biosimilars Of Ranibizumab For Retinal Disorders • North America was the largest region in 2025.

What Is Covered Under Ranibizumab Market?

Ranibizumab is a recombinant humanized monoclonal antibody fragment designed to inhibit the activity of vascular endothelial growth factor A (VEGF-A) in the treatment of various retinal conditions by reducing abnormal blood vessel growth and leakage in the eye. Its advantage lies in its targeted delivery via intravitreal injection, minimizing systemic side effects while preserving and potentially improving vision in affected patients. The main types of ranibizumab include single-use prefilled syringes and single-use glass vials. Single-use ranibizumab syringes are designed for one-time use, filled with the appropriate dosage of ranibizumab before distribution, and disposed of after a single injection. They are used in applications such as wet age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), myopic choroidal neovascularization (MCNV), and retinal vein occlusion (RVO), which are distributed through channels such as hospital pharmacies, online pharmacies, and others.

What Is The Ranibizumab Market Growth Forecast?

The ranibizumab market size is expected to see steady growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to growth in aging population globally, rising diabetes prevalence worldwide, expanding access to advanced ophthalmic care, increasing adoption of intravitreal injections, ongoing improvements in retinal disease screening programs. Major trends in the forecast period include rising adoption of anti-vegf therapies for retinal diseases, growing preference for prefilled syringe formulations, increasing treatment demand for diabetic eye disorders, expansion of ophthalmology specialty care centers, higher use of long-term maintenance therapy in chronic retinal conditions.

What Is The Driver Of The Ranibizumab Market?

The increasing prevalence of eye diseases is expected to propel the growth of the ranibizumab market going forward. Eye diseases encompass a range of conditions affecting the eyes, potentially impairing vision and eye health. The rising prevalence of eye diseases is due to factors such as aging populations and lifestyle changes, along with an increase in chronic conditions like diabetes. Ranibizumab is used to treat conditions such as age-related macular degeneration and diabetic retinopathy, helping to reduce vision impairment in the context of the increasing prevalence of eye diseases. For instance, in August 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 2.2 billion people experience either near or distance vision impairment worldwide. Therefore, the increasing prevalence of eye diseases will drive the growth of the ranibizumab industry.

Key Players In The Global Ranibizumab Market

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries

Global Ranibizumab Market Trends and Insights

Major companies operating in the ranibizumab market are focusing on cost-effective therapies, such as biosimilars of ranibizumab, to treat and prevent vision loss in patients with retinal disorders. A biosimilar of ranibizumab is a biologic medication that is highly similar to the original ranibizumab but is marketed under a different brand name, offering a more affordable alternative while maintaining comparable efficacy and safety profiles. For instance, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biopharmaceutical company, announced the commercial release of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. This launch follows the marketing authorization granted by Health Canada under the brand name Ranopto and Swissmedic under the brand name Ranivisio. FYB201 offers a new, high-quality, effective, and affordable treatment option for patients suffering from severe retinal diseases. It has already demonstrated its significance as a cost-effective treatment choice for patients in the USA and various parts of Europe.

What Are Latest Mergers And Acquisitions In The Ranibizumab Market?

In March 2024, Sandoz Group AG, a Switzerland-based generic pharmaceuticals and biosimilar manufacturer, acquired the CIMERLI business from Coherus BioSciences for an undisclosed amount. With this acquisition, Sandoz aims to enhance its position in the biosimilar market, particularly in ophthalmology, by leveraging Coherus BioSciences expertise in developing biosimilar versions of medications such as Ranibizumab, used in treating eye diseases. Coherus BioSciences is a US-based biopharmaceutical company focused on developing biosimilar versions of medications, such as Ranibizumab.

What Defines the Ranibizumab Market?

The ranibizumab market consists of sales of biosimilars, intravitreal injections, and compounded formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ranibizumab Market Report 2026?

The ranibizumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ranibizumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.